Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSHR | P23945 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14633900 | 0.88 | FSHR (0.51) | FSHRCXCR3SMN1; SMN2HTTNPSR1 | |
| SCHEMBL14633476 | 0.88 | FSHR (0.52) | FSHRPPARGKMT2ADRD2DRD3 | |
| SCHEMBL14633946 | 0.86 | FSHR (0.54) | FSHRSMN1; SMN2KMT2ADRD2DRD3 | |
| SCHEMBL14634120 | 0.85 | FSHR (0.53) | FSHRNPC1KMT2ADRD2DRD3 | |
| SCHEMBL14634004 | 0.84 | FSHR (0.54) | FSHRHTTNPSR1DRD2DRD3 | |
| SCHEMBL14634030 | 0.83 | FSHR (0.57) | FSHRKMT2ADRD2DRD3DRD4 | |
| SCHEMBL14634060 | 0.83 | FSHR (0.53) | FSHRPPARGDRD2DRD3DRD4 | |
| SCHEMBL14633912 | 0.82 | DRD2 (0.53) | FSHRDRD2DRD3DRD4ADRA1A | |
| SCHEMBL14634037 | 0.81 | DRD2 (0.57) | FSHRDRD2DRD3DRD4ADRA1A | |
| SCHEMBL14634002 | 0.81 | DRD2 (0.57) | FSHRDRD2DRD3DRD4ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938262-B2 | Benzamides | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| EP-3263568-A1 | BENZAMIDES | Merck Patent GmbH (DE) | 2018-01-03 | — | — | EP | disclosed |
| EP-2734517-B1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-20170022191-A1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2017-01-26 | — | — | US | disclosed |
| US-9498475-B2 | Benzamides | MERCK PATENT GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| US-20160022670-A1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-9181226-B2 | Benzamides | MERCK PATENT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| EP-2734517-A1 | BENZAMIDES | Merck Patent GmbH (DE) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013012848-A1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2013-01-24 | — | — | WO | disclosed |
| US-20130023522-A1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022670-A1 | BENZAMIDES | FSHR, GNRHR, LHCGR | FSHR 1/4885PPARG 245/4885CXCR3 4544/4885 |
| US-20170022191-A1 | BENZAMIDES | FSHR, GNRHR, LHCGR | FSHR 1/4885PPARG 245/4885CXCR3 4544/4885 |
| US-20130023522-A1 | BENZAMIDES | FSHR, GNRHR, LHCGR | FSHR 1/4885PPARG 328/4885CXCR3 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.